We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00773097
Recruitment Status : Completed
First Posted : October 16, 2008
Results First Posted : February 3, 2014
Last Update Posted : January 7, 2019
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Robert Schoen, University of Pittsburgh

Brief Summary:

The purpose of this study is to evaluate the immune response to MUC1 - poly-ICLC vaccine, an investigational or study vaccine. The MUC1 - poly-ICLC vaccine is being tested in persons with a history of advanced adenomatous polyps, the precursor to colorectal cancer. The MUC1 - poly-ICLC vaccine is being developed to prevent polyps from advancing into colon cancer and to prevent polyps from recurring.

MUC1 is mucus that is normally present on the lining of the human colon. However, MUC1 is expressed in a larger amount and in a modified form on adenomatous polyps and colorectal cancer. These changes in MUC1 are thought to be part of the process of progression from adenomas toward cancer. The goal of a vaccine is to help the immune system in the body identify the changes in MUC1 that accompany the progression to cancer and eliminate the abnormal cells that make abnormal MUC1.

Condition or disease Intervention/treatment Phase
Risk for Colorectal Cancer Biological: MUC1 - Poly ICLC Phase 2

Detailed Description:
This is a phase II trial designed to assess antibody and T cell responses to MUC1 vaccine among subjects at increased risk for colorectal cancer by virtue of a history of advanced adenoma. The primary objective is to evaluate the immunogenicity of a combination of the 100mer MUC1 peptide and adjuvant Poly-ICLC in boosting the immune response to MUC1. Among the secondary objectives is to determine if anti-MUC1 immunity, preexisting or vaccine induced, has an effect on the recurrence of polyps. Subjects with a history of advanced adenoma will be recruited for MUC1 vaccination. Vaccine will be administered at weeks 0, 2, and 10. Some subjects may have pre-existing immunity to MUC1, and this will be accounted for in the analytic phase. However, all subjects will be administered the vaccine, regardless of baseline antibody status. To insure accurate standardization in measurement and assessment of antibody levels, assays for baseline antibody status will be done at the same time as those for response to vaccine.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Study of the MUC1 Peptide - Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
Study Start Date : October 2008
Actual Primary Completion Date : October 2011
Actual Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vaccines

Arm Intervention/treatment
Experimental: MUC1 Poly-ICLC Biological: MUC1 - Poly ICLC
The vaccine will be administered on an outpatient basis in the Digestive Disorders Clinic. The total volume of each dose of vaccine MUC1+ POLY-ICLC will be approximately 250 microliters subcutaneously (SQ) in the upper thigh. The site of injection will remain the same thigh, to enhance the potential immune response.

Primary Outcome Measures :
  1. Number of Participants With Anti Muc-1 Antibody [ Time Frame: 52 weeks ]
    Evaluation of the immune response to MUC1 peptide vaccine administered with Poly-ICLC, measured by Anti MUC1 antibody, in patients with a history of advanced colorectal adenoma.

Secondary Outcome Measures :
  1. Number of Participants With Autoimmune Response to Muc-1 Vaccine [ Time Frame: 52 weeks ]
    Evaluate for autoimmune response by measuring the Anti-muc-1 IgG antibodies to the muc-1 vaccine.

  2. Number of Participants With Adverse Events Associated With the Study Agent [ Time Frame: 54 weeks ]
    Laboratory monitoring including Toxicity laboratory test or monitored through out the study up to week 54.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

-Age 40 - 70 years of age.

  • History of any of the following conditions (operative notes, endoscopy reports, and/or pathology reports must be reviewed locally to confirm that the candidate meets at least one of the following entry criteria).

    1. Colorectal adenoma(s) ≥ 1 cm in maximal diameter
    2. Colorectal adenoma(s) with villous or tubulovillous histology
    3. Colorectal adenoma(s) with high-grade dysplasia
  • Willingness to avoid pregnancy or impregnate (see below) for the period of active study (1 year).
  • ECOG performance status 0 or 1
  • Hemoglobin greater than 95% of the lower limit of institutional normal. Platelets ≥100,000/µL.
  • AST (SGOT), ALT (SGPT), alkaline phosphatase, total bilirubin, BUN, creatinine ≤ 1.5x upper limit of institutional normal.
  • ANA < 1:160

Exclusion Criteria:

  • Receiving any other investigational agents.
  • Presence of an active acute or chronic infection
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agents.
  • History of heritable cancer syndrome (FAP, HNPCC)
  • Patients with a history of auto-immune disease such as, but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, scleroderma, or multiple sclerosis.
  • History of malignancy < 5 years prior to the Registration/Randomization evaluation, excluding non-melanoma skin cancer.
  • Any use of oral corticosteroids ≤ 12 weeks prior to Registration/Randomization.
  • Current or planned use of immunomodulators including: Remicade, 6-MP (Mercaptopurine), Methotrexate, cyclosporine, or other immunomodulatory drugs.
  • Pregnant women, because the teratogenic or abortifacient effects of the study agents remain incompletely defined. Breastfeeding women, because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study agents.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00773097

Layout table for location information
United States, Pennsylvania
Digestive Disorders Clinic
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Robert Schoen
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Robert E Schoen University of Pittsburgh
Publications of Results:
Layout table for additonal information
Responsible Party: Robert Schoen, Principal Investigator, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00773097    
Other Study ID Numbers: PRO07030214
First Posted: October 16, 2008    Key Record Dates
Results First Posted: February 3, 2014
Last Update Posted: January 7, 2019
Last Verified: January 2019
Keywords provided by Robert Schoen, University of Pittsburgh:
Colorectal Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Interferon Inducers
Immunologic Factors
Physiological Effects of Drugs